Regen BioPharma, Inc. is a biotechnology company. The Company is focused on identifying undervalued regenerative medicine applications in the stem cell space. The Company is also focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. Its principal products under development include HemaXellarate I, HemaXellerate II, dCellVax and DiffronC. HemaXellerate I is a cellular therapeutic product indicated for the treatment of damaged bone marrow, which is manufactured using cells collected from the adipose tissue. HemaXellerate II is a version of HemaXellerate that is a universal donor endothelial cell based therapeutic. dCellVax is a cellular therapy that improves the immune system through the process of gene silencing. DiffronC addresses molecular causes that block differentiation. The Company is a wholly owned subsidiary of Bio-Matrix Scientific Group, Inc.